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EDITORIAL
Arachidonic acid in cellular activation
The paper by Huang et al in this issue of Kidney expression, or does it act through modulation of mRNA
International addresses the interesting and still unsettled stability? Are the actions of AA limited to intracellular
question as to whether arachidonic acid (AA), in and of sites, or does its extracellular transport lead to secondary
itself, is a specific pathophysiologic “mediator” of injury, actions in neighboring cells, as is the case for other eico-
independently of its further transformation into oxygen- sanoids? If so, is there an “AA receptor?” Further, AA
ated derivatives [1]. The question is of importance in may activate cellular proteins (such as kinases or phos-
view of the established multiple roles for AA-derived phatases) by direct lipid-protein interactions. It would
autacoids (collectively termed eicosanoids) in numerous be of interest to localize the predominant intracellular
homeostatic and pathologic states [reviewed in 2]. binding site of agonist-stimulated AA, which immedi-
Previous observations in other cell systems had pro- ately precedes its reported stimulation of secondary ki-
posed a role for AA in directly activating interleukin-1 nase activity. Is labeled AA predominantly cytosolic, or
(IL-1) and tumor necrosis factor alpha-induced activa- does it exhibit nuclear binding? Finally, the specificity
tion of the c-jun amino-terminal kinases [3]. Extension of the proposed activator role for AA to initial cellular
of these observations to mesangial cells, as described in activation by IL-1, as compared to numerous other cyto-
this paper, and the support provided through inhibitor- kines/agonists, is of importance in determining the patho-
based studies for the independence of these effects from physiological relevance of the present findings. Since nu-
secondary enzymatic transformation of AA in these cells, merous cytokines, growth factors, lipid-mediators, and
presents highly intriguing implications. Broadly speaking, other cellular activators (notably intracellular calcium
and allowing for a conceptual leap to the domain of concentrations) activate phospholipases, the significance
clinical therapeutics, the findings reported by Huang et al of these studies may be much wider than anticipated. The
raise serious concerns as to whether inhibition of cyclo- complete structural and functional protection afforded by
oxygenases I and/or II, lipoxygenases, or cytochrome P450 an essential fatty acid-deficient diet against experimental
enzymes is an effective strategy in limiting eicosanoid- glomerulonephritis supports a pivotal role for AA in
mediated tissue damage. The release of AA from its mem- mediating inflammatory injury, likely due to the interme-
brane-bound location to a cytosolic site requires only diacy of this essential fatty acid (and/or its metabolites) in
the intermediacy of phospholipase A2 isozymes [2]. If, as the cellular actions of a wide array of pro-inflammatory
proposed here, AA is then capable of directly stimulating cascades [4].
potent cell signaling pathways, such as Jun N-terminal/ Two aspects of the present findings require further
stress-activated protein kinase, inhibition of effects aris- elucidation before a definitive role is assigned to AA as
ing from such activation will require therapeutic inter- an “independent” activator of protein kinases or other
ventions at earlier steps in this key metabolic cascade. intracellular targets. The first relates to the ambient con-
This point is highlighted by the studies performed with centrations required for such effects to become biologi-
the PLA2 inhibitor, aristolochic acid. In addition to these cally relevant. The lowest concentrations eliciting the
“clinical” implications, however, the findings described required effects in the present findings were in the micro-
in these elegant experiments of Huang and colleagues molar range (33 mm). Are such levels attained in the
raise a number of interesting questions on the mechanisms cytosol during activation of mesangial cells by IL-1 or
governing the direct interactions of AA with cellular
other agonists? The second question, raised by the au-
proteins, or, possibly, its regulation of gene expression.
thors in the Discussion section, pertains to the potentialThe most immediately obvious question relates to the
role of non-enzymatically-generated oxygenated prod-means by which AA interacts with elements of gene struc-
ucts of AA, particularly F2-isoprostanes, in the activationture (such as promoters, enhancers, suppressors, etc.) in
of protein kinases. In earlier work, we had demonstrateda specific manner that is not shared by other eicosanoids
the capacity of 8-iso-prostaglandin-F2-alpha (the mostor fatty acids (as suggested by the findings in this report).
abundant isoprostane) to activate mitogen-activated-Does AA act through stimulation or suppression of gene
protein (MAP) kinase in rat aortic smooth muscle cells
[5]. Measurement of kinase activation following stimula-
Key words: cell injury, eicosanoid, cell signaling, gene expression. tion with synthetic isoprostanes, or exogenous IL-1/AA
in the presence of reducing agents, should provide insight 1999 by the International Society of Nephrology
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an arachidonate-dependent mechanism in mesangial cells. Kidneyas to the relevance of isoprostances to the intriguing
Int 55:1740–1749, 1999findings reported in this paper. 2. Breyer MD, Badr KF: Arachidonic acid metabolites and the kid-
ney, in The Kidney (5th ed), edited by Brenner BM, Rector FC.
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